Meet Senior Decision Makers 500 senior attendees from leading pharmaceutical, biopharmaceutical, academics, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, & Managers with the following job titles: Discover New Solutions Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include: Day 3: Oligonucleotide Therapeutics & Manufacturing • Evaluating oligonucleotides as personalised medicines • Therapeutic antisense oligonucleotides • Addressing CMC considerations for oligonucleotides • Process Analytical Technologies • Toxicology testing for oligos • Quality assurance • Case studies from the areas of: o Oncology o Genetic disorders o Cardiovascular diseases Day 2 Stream 1: Peptide Design, Synthesis, Analytical Technologies • Toxicity testing in pre-clinical stage • Computer-aided design • Overcoming the challenges in peptide aggregation • Analytical and bioanalytical strategies for peptide development • Early peptide analytics and characterization • Novel strategies for improving peptide properties: stability and half-life extension Day 2 Stream 2: Peptide Purification, Manufacturing & Process Development • Advances in manufacturing technologies for peptides • New approaches to manufacture therapeutic peptides • Regulatory strategies to manufacture peptides on a commercial scale • Recent advancements in the processes of manufacturing peptides • Advances in the HPLC purification of peptides • Day 3 Stream 1: Peptide Therapeutics: Peptide Therapeutics Case Studies, Immunogenicity & Novel Disease Treatments • Therapeutics case studies from the areas of: o Metabolic disorders: ➢ Obesity ➢ Diabetes ➢ Osteoporosis o Endocrinology o Immunology o Oncology o Infectious diseases • Improving the immunogenicity of peptides • New peptides for novel disease treatments: case studies • Antimicrobials Peptide Screening Peptide Formulation Peptide Characterisation Oligonucleotides Oligo Synthesis Oligo Characterisation Peptide Synthesis Peptide Array Technologies Display Technologies Oligo Synthesis Oligo Design Tools Therapeutics Development OLIGONUCLEOTIDE-FOCUSED STREAMS: Day 2: Oligonucleotide Synthesis, Chemistry, Formulation & Delivery, Process & Analytical Development • Advanced synthesis technologies for oligos • Oral delivery of oligos – overcoming key challenges • Improving the potency of oligos • Purification technology development: o Freeze-drying o Chromatography • Impurity analysis • Designing antisense oligos • Making stable & quality oligos PEPTIDE-FOCUSED STREAMS: Day 1: Kick-Off Session – Turning Challenges to Successes in Peptide Delivery and Formulation • Oral delivery of peptides • Novel formulation strategies for peptides • Novel peptide delivery strategies • Enhancing peptide bioavailability • Updates in stability of peptide therapeutics • Developing stable peptide formulations • Peptide display technologies The event form part of our successful Biologics Series; co- located with the 13 th Annual Proteins & Antibodies Congress and 2 nd Annual Bispecifics in Discovery & Development Congress. 2020 Speakers Include: Nigel Richardson Jennifer Franklin Rami Hannoush GlaxoSmithKline IONIS Pharmaceuticals Genentech
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Meet Senior Decision Makers
500 senior attendees from leading pharmaceutical, biopharmaceutical,
academics, CRO and solution provider companies will be attending. Meet
Senior VPs, Directors, & Managers with the following job titles:
Discover New Solutions
Formal and informal meeting opportunities offer delegates the
chance to discuss key solutions with leading service providers.
Services to be discussed include:
Day 3: Oligonucleotide Therapeutics & Manufacturing
• Evaluating oligonucleotides as personalised medicines
• Therapeutic antisense oligonucleotides
• Addressing CMC considerations for oligonucleotides
• Process Analytical Technologies
• Toxicology testing for oligos
• Quality assurance
• Case studies from the areas of:
o Oncology
o Genetic disorders
o Cardiovascular diseases
Day 2 Stream 1: Peptide Design, Synthesis, Analytical
Technologies
• Toxicity testing in pre-clinical stage
• Computer-aided design
• Overcoming the challenges in peptide aggregation
• Analytical and bioanalytical strategies for peptide
development
• Early peptide analytics and characterization
• Novel strategies for improving peptide properties: stability
and half-life extension
Day 2 Stream 2: Peptide Purification, Manufacturing &
Process Development
• Advances in manufacturing technologies for peptides
• New approaches to manufacture therapeutic peptides
• Regulatory strategies to manufacture peptides on a
commercial scale
• Recent advancements in the processes of manufacturing
peptides
• Advances in the HPLC purification of peptides
•
Day 3 Stream 1: Peptide Therapeutics:
Peptide Therapeutics Case Studies, Immunogenicity & Novel
Disease Treatments
• Therapeutics case studies from the areas of:
o Metabolic disorders:
➢ Obesity
➢ Diabetes
➢ Osteoporosis
o Endocrinology
o Immunology
o Oncology
o Infectious diseases
• Improving the immunogenicity of peptides
• New peptides for novel disease treatments: case studies
• Antimicrobials
Peptide Screening
Peptide Formulation
Peptide Characterisation
Oligonucleotides
Oligo Synthesis
Oligo Characterisation
Peptide Synthesis
Peptide Array Technologies
Display Technologies
Oligo Synthesis
Oligo Design Tools
Therapeutics Development
OLIGONUCLEOTIDE-FOCUSED STREAMS:
Day 2: Oligonucleotide Synthesis, Chemistry, Formulation &
Delivery, Process & Analytical Development
• Advanced synthesis technologies for oligos
• Oral delivery of oligos – overcoming key challenges
• Improving the potency of oligos
• Purification technology development:
o Freeze-drying
o Chromatography
• Impurity analysis
• Designing antisense oligos
• Making stable & quality oligos
PEPTIDE-FOCUSED STREAMS:
Day 1: Kick-Off Session – Turning Challenges to Successes in
Peptide Delivery and Formulation
• Oral delivery of peptides
• Novel formulation strategies for peptides
• Novel peptide delivery strategies
• Enhancing peptide bioavailability
• Updates in stability of peptide therapeutics
• Developing stable peptide formulations
• Peptide display technologies
The event form part of our successful Biologics Series; co-
located with the 13th Annual Proteins & Antibodies Congress
and 2nd Annual Bispecifics in Discovery & Development
Congress.
2020 Speakers Include:
Nigel Richardson Jennifer Franklin Rami Hannoush
GlaxoSmithKline IONIS Pharmaceuticals Genentech
2020 Peptides Confirmed Speakers:
• Thomas Vorherr, Director Peptide Discovery, Novartis
• Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics
• David Earp, President and Chief Executive Officer, Circle Pharma
• Ali Tavassoli, Founder and Chief Scientific Officer, Curve Therapeutics
• Olivier Kitten, Founder and Chief Executive Officer, Affilogic
• Alex Batchelor, Chief Executive Officer, Orbit Discovery
• Andrew Young, Chief Scientific Officer, Intarcia Therapeutics
• Laura Itzhaki, Chief Scientific Officer, PolyProx Therapeutics
• Fabrizio Badalassi, Director Chemical Development, Ferring Pharmaceuticals
• Maria Van Dongen, Head of External Innovation, Discovery Sciences, Janssen
• Mathias Schaffrath, Group Head Purification, Sanofi
• Rami Hannoush, Principal Scientist, Genentech
• Jesper Soendergaard Marino, Principal Scientist, Novo Nordisk
• Andreas Hoijer, New Modality Formulation Team Leader, AstraZeneca
• Linda Thunberg, Associate Principal Scientist, AstraZeneca
• Nagy Habib, Professor and Head of the Surgery Hammersmith Campus, Imperial College London
• Jesper Wengel, Professor of Nucleic Acid Center, University of Southern Denmark
• Andre Gerber, Professor of RNA Biology, University of Surrey
• Frank Sobott, Chair in Biomolecular Mass Spectrometry, University of Leeds
• Andrew Livingston, Professor of Chemical Engineering, Queen Mary, University of London
• Afaf El-Sagheer, Professor, University of Oxford
• Haiyan Zhou, Principal Investigator and Group Leader, University College London
• David Williams, Reader in Chemical Biology, University of Sheffield
2020 Biologics Series UK Sponsors:
Platinum Sponsors:
Gold Sponsors:
Silver Sponsors:
Benefits to Attending
✓ Hear from and meet with the key innovators in the peptide & oligonucleotide field. Previous attendees included:
Senior Vice President, Ferring Pharmaceuticals; Senior Director, Johnson & Johnson; Director, Novo Nordisk
✓ Discover collaborative solutions to peptide formulation and delivery. Join the kick-off sessions and discuss novel
peptide delivery strategies, oral delivery of peptide-based therapeutics and developing stable peptide formulations
✓ Discuss the latest innovations in peptide synthesis and analytical technologies. Presentations will delve into
oligonucleotide synthesis, advances in HPLC peptide purification, and computer-aided design
✓ New to 2020! Learn more about oligonucleotide synthesis, chemistry, formulation & delivery. Presentations will tap into
advanced synthesis technologies for oligos, improving their potency and addressing the key challenges in their oral
delivery
✓ New to 2020! Gain a comprehensive understanding of oligonucleotide therapeutics & manufacturing. Hear about CMC
considerations for oligos as well as case studies from therapeutic areas such as oncology and infectious diseases
✓ A high-quality programme devised with the help of our esteemed advisory board. Presentations will cover oral
delivery of peptide-based therapeutics, synthesis of oligonucleotides, therapeutic peptide manufacturing
Bronze Sponsors:
Networking and Programme Sponsors:
7th Annual Peptides & Oligonucleotides Congress
Day One – 27 April 2020
7th Annual Peptides & Oligonucleotides Congress
08.00 – 08.30 Registration
08.30 – 11.30 Workshop led by:
Chemical Computing Group
11.00 – 11.30 Registration & Welcome Refreshments
Kick-Off Session – Turning Challenges To Successes In Peptide Delivery and Formulation
• Oral delivery of peptides
• Novel formulation strategies for peptides
• Novel peptide delivery strategies
• Updates in stability of peptide therapeutics
• Developing stable peptide formulations
11.30 – 12.00 Kick Off Session Keynote:
The Obstacles That Bioavailability Represents To Peptide Formulation
Andreas Hoijer, New Modality Formulation Team Leader, AstraZeneca
12.00 – 12.30 Roundtable Discussion
12.30 – 13.15 Lunch
13.15 – 13.45 Designing Peptides For The Medici Drug Delivery System: Integration Of Drug-Device Design
• Attributes and constraints of Intarcia’s mini-osmotic pump
• Strategies for maximizing therapeutic effects, and minimizing adverse effects
Andrew Young, Chief Scientific Officer, Intarcia Therapeutics
13.45 – 14.15 Sponsor Presentation
14.15 – 14.45 Panel Discussion
14.45 – 15.15 The Impact Of Metabolism On Oral Bioavailability Of Peptides
In the first instance, strategies aiming at peptide modifications to maintain or to enhance solubility, while enabling permeability and good exposure upon oral
administration are discussed. The presentation then focuses on our latest insights with respect to metabolism of cyclic peptides, and how hot spots are resolved to
achieve excellent oral bioavailability. In this context, analyses of metabolites, the validation of metabolically stable isosteres for Leu and Pro, and their effect on
exposure and oral uptake in rats are reported.
Thomas Vorherr, Director Peptide Discovery, Novartis
15.15 – 15.45 Developability And Preformulation Of Peptides
Jette Boll, Senior Scientist, Ferring
7th Annual Peptides & Oligonucleotides Congress
Day One – 27 April 2020
15.45 – 16.00 Refreshments
16.00 – 16.10 Oxford Global’s Welcome Address
16.10 – 17.10 Welcome Keynote: The Current Landscape And Future Opportunities In Biologics Research – An AstraZeneca Case Study
Tristan Vaughan, Vice President R&D, Antibody Discovery & Protein Engineering, AstraZeneca
16.00 – 16.30 Peptide Therapeutics Application Within Infectious Diseases
Li Li, Principal Scientist, Merck
Nanostar Sieving For Liquid Phase Synthesis Of Oligonucleotides
• More than 130 oligonucleotide drugs are in trials and many of these for mainstream medical
needs. This is creating an imperative to develop scalable technology to manufacturfe oligos at
the multi-ton scale
• Nanostar seiving uses iterative synthesis via protecting groups coupled to nanomembranes to
sieve the growing oligos from reaction debris, so that the whole synthesis is carried out in the
liquid phase
• Oligos produced by nanostar sieving are more than 90%pure before chromatograhpy; the
process can be scaled to any bacth size; and because it is liquid phase process controls can be
used to ensure quality
Andrew Livingston, Professor of Chemical Engineering, Queen Mary, University of London
16.30 – 17.00 Targeted, Controlled And Responsive Therapeutic Delivery Through The Design Of
Self-Assembling Peptide Hydrogels
• Design rules for engineering responsive peptide hydrogels
• Targeting endometriosis with sprayable peptide hydrogels
• Delivery of therapeutics to solid tumors
• Mucoadhesive hydrogels to prolong therapeutic efficacy
Aline Miller, Professor, University of Manchester
Strategies For Identity Testing OF Oligonucleotide Therapeutics
Nadim Akhtar, Principal Scientist Characterisation & Control Strategy, AstraZeneca
17.00 – 17.30 Potential Applications For Immune-Boosting Peptides
• Global unmet needs exist in the fields of cancer immunotherapy, overcoming deleterious
effects of UV irradiation on the skin, development of non-opioid analgesics and drug
addiction
• Peptides that boost the immune system may offer therapeutic options that complement
existing strategies to address the above challenges
Michael Agrez, Chief Executive Officer, InterK Peptide Therapeutics
Evaluating Oligonucleotides As Personalised Medicines
Haiyan Zhou, Principal Investigator and Group Leader, University College London
7th Annual Peptides & Oligonucleotides Congress
Day Three – 29 April 2020
Peptide Therapeutics
Oligonucleotide Therapeutics & Manufacturing
17.30 – 18.00 Peptide Modalities (For In Situ Optical Imaging): From Bench To Humans
Sunay Chankeshwara, Associate Principal Scientist, Senior Expert Peptide Chemistry,
AstraZeneca
The Oligonucleotide Agent BC 007 For Neutralization Of Functionally Active Pathogenic
Autoantibodies Directed Against ß 1-Adrenoceptors In Heart Failure Patients – First
Phase II Data
• Functionally active pathogenic autoantibodies (fAAb) against G-protein coupled receptors
(fGPCR-AAbs) are triggers and sustainers of a variety of diseases, mostly affecting the heart and
vascular system as e.g. heart failure (HF; here autoantibodies against the β1-adrenoceptor (fβ1-
AAb)) or pulmonary arterial hypertension (here fAAB against the endothelin ETA-receptor) and
sinus bradycardia (fAAB against the muscarinic M2 receptor)
• As already seen in elderly healthy but fGPCR-AAb positive volunteers in Phase-I, BC 007
neutralizes these fAAbs in patients with progressed HF as well
• Besides this demonstrated mode of action, Phase-I safety tests showed an excellent tolerability,
no clinically relevant side effects. Transient elevated aPTT to subclinical values, paralleling the
infusion, were observed in some subjects
• A two-arm randomized, open-label Phase-IIa study, investigating the temporal persistence of the
fβ1-AAb neutralization, safety and pharmacokinetic in chronic HF patients with reduced ejection
fraction, including twenty β1-AAb positive HF patients and ten positive patients who serve as
controls, is currently running. First efficacy data will be presented
Annekathrin Haberland, Director, Regulatory Affairs, Berlin Cures
18.00 End of Conference
I cannot attend but would like to purchase access to the following:
Access to the online conference presentations £499 plus VAT VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.
Biologics Series
13th Annual Proteins & Antibodies Congress | 7th Annual Peptides & Oligonucleotides Congress 2nd Annual Bispecifics in Discovery & Development Congress
27 - 29 April 2020, Novotel London West, London, UK www.oxfordglobal.co.uk/biologics-series/
HOW TO REGISTER: FAX your booking form to +44(0)1865 689120 | PHONE on +44(0)1865 248455 | EMAIL: [email protected]
Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate: Delegate Booking Fee The Delegate Booking Fee includes: lunches and refreshments throughout the Series, presentations and panel sessions, scheduled one-to-one meetings and networking/social events, Series and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser.
An admin surcharge of £50 plus VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.
Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.
Acceptance of a Complimentary Pass If you are offered a free delegate pass and you are unable to attend the Series, you may nominate a substitute of equal standing (in terms of business and financial responsibility). A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid a non-attendance charge of £200 plus VAT being applied. Your complimentary delegate place is not officially confirmed until we have had chance to check that you qualify for the complimentary pass. Please do not make any travel arrangements before we have confirmed acceptance of your application. We will not be liable for any expenses incurred.
Delegate Registration Form Each Delegate must complete the online delegate registration form issued by the Organiser on receipt of the Delegate Booking Form. This information will only be used for the organisation of the Series, for material produced for Delegates and Sponsors and to facilitate the networking sessions.
Cancellation and Curtailment If a Registered Delegate is unable to attend the Series, he/she may nominate a substitute of equal standing within their Company. A substitute delegate must be nominated within a week of cancellation and must be approved by the Organiser in advance in order to avoid cancellation charges being applied. Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.
More than 6 months prior 35% cancellation fee / 65% refund Between 6 and 3 months prior 75% cancellation fee / 25% refund Less than 3 months prior to the event Full cancellation fee / No refund
Data Protection The data controller is the organiser (Oxford Global Marketing Ltd). The Organiser may disclose such personal information as name, company, job title, telephone and email address to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Series. Registration details will be retained and used in accordance with our privacy policy. If you wish to opt out please email [email protected]
Miscellaneous The Organiser will determine the scope and content of Series events, seminars, workshops and activities throughout the Series. The Organiser reserves the right to cancel the Series without liability to Delegate’s Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Series, the Organiser reserves the right to transfer this Booking to another Series within the same sector to be held within twelve months. Should another Series in the same sector not be available within this period, the Booking Fee will be refunded. For promotional purposes, there may be professional photography and video production taking place during the Series. Delegates who do not wish to be filmed or recorded should advise the organisers by email to [email protected] prior to the event. These terms and conditions are binding upon the delegate submitting a registration form.
If you have any further queries please call the marketing team on +44(0)1865 248455 or email [email protected]
Delegate Details
Terms & Conditions of Booking
I agree to the above Terms and Conditions
Registration Fees
Documentation
How to Pay (choose one of the following payment options)
I would like to attend: (Please tick as appropriate) Industry Delegates (Biopharma, Pharma or Biotech Companies) 2-day pass £899 plus VAT 1-day pass £599 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Academic Delegates 2-day pass £520 plus VAT 1-day pass £320 plus VAT Day 1 (with complimentary access to the pre-event workshop) Day 2 Day 3 Vendor Delegates (CROs, Consultants, Technology and Service Providers) Series Only £1750 plus VAT Poster Presentation £250 plus VAT PROMOTIONAL LITERATURE DISTRIBUTION Distribution of your company’s promotional literature to all Series attendees £999 plus VAT
Number of delegates:
Industry del(s) Academic dels(s) Vendor dels(s)
Special Offer: 3 for 2 Offer is only valid on the Series and for those registering at Industry or Academic rates
Please choose one of the following payment options:
CREDIT CARD:
An Oxford Global representative will contact you directly following return of contract / booking form to process card payment. If payment will be made by a colleague within your company, please complete the following;
*Please note there is a £50 plus VAT handling charge for payment via invoice
Please complete fully and clearly. Please photocopy for additional delegates. Please tick which event(s) in the Series you are interested in: Proteins & Antibodies Congress Bispecifics Congress Peptides & Oligonucleotides Congress Title:_____ Forename:__________________ Surname:__________________ Job Title:___________________________________________________________ Company/Organisation:___________________________________________ Email:_____________________________________________________________ Address:___________________________________________________________ Postcode: ________________________ Country: _________________________ Direct Telephone _______________ Direct Fax: ________________ Mobile: ________________________ Switchboard: _____________ Signature: ______________________ Date: ___________________________